Iterum Therapeutics: A Sound Investment Amidst Market Volatility? In today's volatile market, discerning investors are constantly on the lookout for promising ventures that offer a strong return potential. One such opportunity that has piqued interest is Iterum Therapeutics (NASDAQ: $ITRM), a clinical-stage pharmaceutical company focused on developing anti-infectives to combat multi-drug resistant pathogens. Recently, HC Wainwright...
$Iterum Therapeutics(ITRM.US)$• Ireland-based pharma said it would resubmit its new drug application (NDA) for its oral anti-infective compound, sulopenem, with the FDA in the first half of Q2 2024 sooner than its initial plans. • The company said that the filing would address the concerns the regulator raised in July 2021 when it declined to approve the product. At the time, the company targeted sulopenem for patients with urinary tract infections caused byquinolone non-susceptible pathogens. ...
Trytosaveabit楼主Super Waves:
Had to average down a bit! But that’s why my swing trades, i buy a bit at a time expecting a pullback! That allows be to buy more without buying more shares than I wanted to without being surprised by it!
Trytosaveabit楼主Super Waves:
Why thank you! Hehehe! Yeah it works really well for swing trades! Especially the ones where you know that great PR is coming soon, but not positive when exactly!
Iterum Therapeutics股票讨论区
NEWS
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
Dow Jones· 2 mins ago
In today's volatile market, discerning investors are constantly on the lookout for promising ventures that offer a strong return potential. One such opportunity that has piqued interest is Iterum Therapeutics (NASDAQ: $ITRM), a clinical-stage pharmaceutical company focused on developing anti-infectives to combat multi-drug resistant pathogens. Recently, HC Wainwright...
• The company said that the filing would address the concerns the regulator raised in July 2021 when it declined to approve the product. At the time, the company targeted sulopenem for patients with urinary tract infections caused by quinolone non-susceptible pathogens.
...
暂无评论